Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia

被引：0

作者：

张仪 ^{[1
]}

机构：

[1] 1st Affil Hosp,Zhejiang Univ

来源：

China Medical Abstracts(Internal Medicine) | 2016年 / 33卷 / 04期

关键词：

AML; IA; were; Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia; for; of; with;

D O I：

暂无

中图分类号：

R733.71 [急性白血病];

学科分类号：

100214 ;

摘要：

Objective To compare the efficacy,safety and longterm prognosis between different dose idarubicin(IDA)combined with cytarabine(IA)as induction chemotherapy in newly diagnosed young patients of acute myeloid leukemia(AML).Methods A total of 149 newly diagnosed young AML patients(APL excluded)between January 2009 to July 2014 was enrolled.According to the

引用

页码：231 / 231

页数：1

共 50 条

[31] Intensive chemotherapy in induction and consolidation for de novo adult acute myeloid leukemia using sequential courses of high dose cytarabine, idarubicin, and etoposide; a randomized trial of the Australasian Leukaemia and Lymphoma Group (ALLG).
Bradstock, KF
Young, GA
Lowenthal, RM
Matthews, JP
BLOOD, 2001, 98 (11) : 462A - 462A
[32] Intensification of induction by high-dose AraC and outcome in older patients with de-novo acute myeloid leukemia (AML) and subsets.
Buchner, Thomas
Berdel, Wolfgang E.
Schoch, Claudia
Haferlach, Torsten
Tchinda, Joelle
Schnittger, Susanne
Kern, Wolfgang
Reichle, Albrecht
Staib, Peter
Serve, Hubert L.
Ludwig, Wolf-Dieter
Sauerland, Maria Cristina
Heinecke, Achim
Wormann, Bernhard Josef
Hiddemann, Wolfgang
BLOOD, 2006, 108 (11) : 560A - 560A
[33] DE-NOVO ACUTE MYELOID-LEUKEMIA IN PATIENTS WITH CROHNS-DISEASE
DOMBRET, H
MAROLLEAU, JP
NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1995, 37 (03): : 193 - 196
[34] Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
Zhang, Qi
Zhang, Chun-Hong
Wang, Zhen-Dong
Wang, Dong
TUMORI JOURNAL, 2022, 108 (02): : 182 - 188
[35] Idarubicin, high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia
Mehta, J
Powles, R
Singhal, S
Horton, C
Prediville, J
Glynne, P
Zomas, A
Hamblin, S
Saso, R
Mackay, H
Treleaven, J
BLOOD, 1995, 86 (10) : 2041 - 2041
[36] High-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia: The effect of additional idarubicin.
Mehta, J
Powles, R
Treleaven, J
Kulkarni, S
Swansbury, GJ
Hamblin, M
Saso, R
Killick, S
Rege, K
Singhal, S
BLOOD, 1997, 90 (10) : 2259 - 2259
[37] Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Yesid Alvarado
Apostolia Tsimberidou
Hagop Kantarjian
Jorge Cortes
Guillermo Garcia-Manero
Stefan Faderl
Deborah Thomas
Elihu Estey
Francis J. Giles
Cancer Chemotherapy and Pharmacology, 2003, 51 : 87 - 90
[38] Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia
Oriol, A
Ribera, JM
Brunet, S
Esteve, J
Bueno, J
Llorente, A
HAEMATOLOGICA, 2003, 88 (02) : 229 - 230
[39] Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Alvarado, Y
Tsimberidou, A
Kantarjian, H
Cortes, J
Garcia-Manero, G
Faderl, S
Thomas, D
Estey, E
Giles, FJ
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (01) : 87 - 90
[40] High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years
Arellano, Martha
Winton, Elliott
Pan, Lin
Lima, Lisa
Tighiouart, Mourad
Bhalla, Kapil
Heffner, Leonard T.
Neely, Jessica
Hutcherson, Donald
McLemore, Morgan
Langston, Amelia
Khoury, H. Jean
CANCER, 2012, 118 (02) : 428 - 433

← 1 2 3 4 5 →